Sipuleucel-T shows partial advantage in prostate cancer.
Gould
Paula
P
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D015996:Survival Rate; D014020:Tissue Extracts / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T